Surrozen, Inc. (SRZN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は South San Francisco, CA, アメリカ. 現CEOは Craig C. Parker.
SRZN を有する IPO日 2021-01-11, 40 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $232.32M.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
